Sign Up for Email Alerts
Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
  • Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
  • Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
  • Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
  • Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta’s VISTA blocking antibody Currently in Phase 1
April 3, 2021 in KVA1213 Publications

A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

Kineta Inc 0 Like Post Comments Off on A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

Thierry Guillaudeux, PhD, Chief Scientific Officer American Association for Cancer Research (AACR) Annual Meeting 2021 | April, 2021

Read More

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • About Us
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2025 Kineta Inc.        Privacy Policy       Terms of Use

English
English
Korean